Trial Profile
A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Nanogen
- 29 Dec 2017 New trial record